Literature DB >> 26562503

PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development.

Aaron R Hansen1, Lillian L Siu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26562503     DOI： 10.1001/jamaoncol.2015.4685

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  47 in total

Review 1.  Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we?

Authors:  Matthew Evans; Brendan O'Sullivan; Matthew Smith; Philippe Taniere
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 2.  Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.

Authors:  Marius Ilie; Véronique Hofman; Manfred Dietel; Jean-Charles Soria; Paul Hofman
Journal:  Virchows Arch       Date:  2016-02-25       Impact factor: 4.064

3.  PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.

Authors:  Joel C Sunshine; Peter L Nguyen; Genevieve J Kaunitz; Tricia R Cottrell; Sneha Berry; Jessica Esandrio; Haiying Xu; Aleksandra Ogurtsova; Karen B Bleich; Toby C Cornish; Evan J Lipson; Robert A Anders; Janis M Taube
Journal:  Clin Cancer Res       Date:  2017-04-20       Impact factor: 12.531

4.  PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes.

Authors:  Jordan Roberts; Safia N Salaria; Justin Cates; Yang Wang; Cindy Vnencak-Jones; Jordan Berlin; Chanjuan Shi
Journal:  Am J Clin Pathol       Date:  2019-08-01       Impact factor: 2.493

Review 5.  Emerging biomarkers and targeted therapies in urothelial carcinoma.

Authors:  Prateek Mendiratta; Petros Grivas
Journal:  Ann Transl Med       Date:  2018-06

Review 6.  Towards tumor immunodiagnostics.

Authors:  Helen Kourea; Vassiliki Kotoula
Journal:  Ann Transl Med       Date:  2016-07

Review 7.  Genomic correlates of response to immune checkpoint blockade.

Authors:  Tanya E Keenan; Kelly P Burke; Eliezer M Van Allen
Journal:  Nat Med       Date:  2019-03-06       Impact factor: 53.440

8.  Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies.

Authors:  Lillian L Siu; S Percy Ivy; Erica L Dixon; Amy E Gravell; Steven A Reeves; Gary L Rosner
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

Review 9.  Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?

Authors:  D-W Sun; L An; H-Y Huang; X-D Sun; G-Y Lv
Journal:  Clin Transl Oncol       Date:  2020-05-27       Impact factor: 3.405

10.  Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.

Authors:  Douglas B Johnson; Garrett M Frampton; Matthew J Rioth; Erik Yusko; Yaomin Xu; Xingyi Guo; Riley C Ennis; David Fabrizio; Zachary R Chalmers; Joel Greenbowe; Siraj M Ali; Sohail Balasubramanian; James X Sun; Yuting He; Dennie T Frederick; Igor Puzanov; Justin M Balko; Justin M Cates; Jeffrey S Ross; Catherine Sanders; Harlan Robins; Yu Shyr; Vincent A Miller; Philip J Stephens; Ryan J Sullivan; Jeffrey A Sosman; Christine M Lovly
Journal:  Cancer Immunol Res       Date:  2016-09-26       Impact factor: 11.151
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.